arcadia biosciences glp-1 receptor agonist weight management diabetes treatments Agonists For Obesity In Non-Diabetic Patients: Game Changer Or Overhyped? A Critical Analysis GlobalRPH Oral GLP-1-Based Therapeutics in the

Exenatide, a 39-amino acid peptide, is the first GLP-1R agonists approved by the US FDA in 2005 and EMA in 2007

Understanding metabolic memory: the prolonged influence of glycemia during the Diabetes Control and Complications Trial (DCCT) on future risks of complications during the study of the epidemiology of diabetes interventions and complications (EDIC)

Lilly and Nimbus have been partnering for more than three years on developing a small molecule activator of a specific isoform of AMP-activated protein kinase (AMPK) to treat cardiometabolic diseases, under an up-to-$496 million partnership launched in 2022

& Liu, F

Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)A multicentre, double-blind, randomised, placebo-controlled trial